Tonmya for Post-Traumatic Fibromyalgia: Pharmacy Lien Guide

Amar Lunagaria — Co-Founder & Chief Pharmacist, LienScripts | March 29, 2026 | 7 min read

Tonmya (cyclobenzaprine sublingual) is the first FDA-approved treatment purpose-built for fibromyalgia, making it a powerful documentation tool for post-traumatic fibromyalgia cases on pharmacy lien. This guide explains the clinical significance, prescribing context, and settlement implications for PI attorneys.

Tonmya (TNX-102 SL, cyclobenzaprine sublingual) is the first medication developed and FDA-approved specifically for the treatment of fibromyalgia, and its prescription in a personal injury case documents a specific fibromyalgia diagnosis with a specificity that off-label medications like duloxetine and pregabalin cannot match. For attorneys handling post-traumatic fibromyalgia cases — fibromyalgia triggered by physical trauma from an accident — Tonmya in the pharmacy record provides a direct link between the injury and a chronic, medication-requiring condition that defense counsel cannot easily dismiss as vague or subjective.

• Tonmya is a sublingual formulation of cyclobenzaprine (2.8mg or 5.6mg at bedtime) purpose-built for fibromyalgia, with pharmacokinetics optimized for sleep architecture improvement and central pain modulation — distinct from standard oral cyclobenzaprine used as a muscle relaxant
• The RESILIENCE trial demonstrated significant improvement in fibromyalgia pain and sleep quality versus placebo, meeting primary and key secondary endpoints (Tonix Pharmaceuticals; FDA approval 2025)
• LienScripts covers Tonmya on pharmacy lien for post-traumatic fibromyalgia cases, and each case receives a MERIT (Medication Evaluation & Rationale for Injury Treatment) report identifying the fibromyalgia-specific medication in the treatment record
• According to James Wong, PharmD, founder of LienScripts, "Before Tonmya, every fibromyalgia medication was borrowed from another indication — duloxetine from depression, pregabalin from neuropathy. Tonmya is the first drug where the sole purpose is fibromyalgia, and that changes the documentation equation"
• Post-traumatic fibromyalgia develops in approximately 22% of patients following significant physical trauma, making it one of the most common chronic pain conditions in PI cases (Buskila et al., Arthritis & Rheumatism, 1997)

How Tonmya Differs from Standard Cyclobenzaprine

Standard oral cyclobenzaprine (Flexeril, 5-10mg three times daily) is a well-known muscle relaxant prescribed for acute musculoskeletal spasm. Defense experts and adjusters recognize it as a conservative, short-term medication.

Tonmya is fundamentally different:

1. Dose: 2.8mg or 5.6mg (much lower than standard cyclobenzaprine)
2. Route: Sublingual (dissolved under the tongue), providing different absorption and metabolism
3. Timing: Once daily at bedtime (not three times daily for muscle spasm)
4. Indication: FDA-approved specifically for fibromyalgia (not muscle spasm)
5. Mechanism: At the sublingual low dose, cyclobenzaprine modulates sleep architecture and central pain processing rather than simply relaxing muscles

[!KEY] Tonmya and standard cyclobenzaprine are clinically different medications despite sharing the same active ingredient. The sublingual route, low dose, bedtime administration, and fibromyalgia-specific FDA approval make Tonmya a diagnostic medication — its prescription inherently documents a fibromyalgia diagnosis, not a muscle spasm complaint.

Post-Traumatic Fibromyalgia: The Clinical Connection

Fibromyalgia triggered by physical trauma — post-traumatic fibromyalgia — is well-documented in the medical literature. The mechanism involves:

1. Initial injury — accident causes musculoskeletal trauma
2. Peripheral sensitization — ongoing pain signals from the injury site alter peripheral nerve sensitivity
3. Central sensitization — repeated pain input alters spinal cord and brain pain processing
4. Widespread pain amplification — the central nervous system begins amplifying pain signals throughout the body, not just at the injury site
5. Fibromyalgia diagnosis — widespread pain, fatigue, sleep disturbance, and cognitive difficulties meeting ACR diagnostic criteria

Buskila et al. demonstrated that 22% of patients with neck injuries from motor vehicle accidents developed fibromyalgia within 3-6 months, compared to only 2% of patients with lower extremity fractures — suggesting that cervical trauma is a particularly potent trigger for fibromyalgia development.

As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist explains, "The temporal relationship between the accident and the fibromyalgia diagnosis is the foundation of these cases. The pharmacy record shows when fibromyalgia treatment began relative to the accident date, and Tonmya specifically documents that the treating provider diagnosed fibromyalgia — not just generalized pain."

Why Tonmya Strengthens PI Cases

1. Diagnostic Specificity

Duloxetine is prescribed for depression, anxiety, neuropathic pain, and fibromyalgia. Pregabalin is prescribed for neuropathic pain, seizures, and fibromyalgia. When these medications appear in the pharmacy record, defense can argue they were prescribed for a non-fibromyalgia indication.

Tonmya has one indication: fibromyalgia. Its presence in the pharmacy record is unambiguous diagnostic documentation.

2. FDA Validation

The FDA approval validates fibromyalgia as a real, treatable medical condition — a point still contested by some defense medical experts. A medication that passed FDA clinical trials for fibromyalgia carries regulatory authority that defense opinions cannot override.

[!TIP] If a defense IME report questions the fibromyalgia diagnosis, Tonmya's FDA approval provides a powerful rebuttal. The FDA determined, through rigorous clinical trials, that fibromyalgia is a condition that responds to pharmacological treatment. The treating provider's prescription of an FDA-approved fibromyalgia medication is inherently more credible than a defense opinion dismissing the diagnosis.

3. Treatment Commitment

Tonmya is taken daily, indefinitely. Each monthly refill documents ongoing fibromyalgia requiring continuous pharmacological management. Over 12-24 months, the refill record creates an irrefutable timeline of chronic disease.

4. Cost Documentation

As a newly approved branded medication with no generic equivalent, Tonmya carries premium pricing. This is not a provider's choice of brand over generic — it is the only available formulation of fibromyalgia-specific sublingual cyclobenzaprine. Defense arguments about cheaper alternatives fail.

The Fibromyalgia Medication Stack

Tonmya is often prescribed alongside other medications in a multi-drug fibromyalgia regimen:

• Tonmya (bedtime) — sleep architecture and central pain modulation
• Duloxetine 60-120mg — descending pain inhibition and mood
• Pregabalin 300-600mg or gabapentin 1800-3600mg — neural hyperexcitability
• Low-dose naltrexone 1.5-4.5mg — glial cell modulation (compounded)
• Topical agents — localized pain management at tender points

This multi-drug regimen documents the complexity of fibromyalgia management. LienScripts covers all medications in the fibromyalgia stack on pharmacy lien and generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report presenting the complete regimen.

[!KEY] A fibromyalgia case treated with Tonmya, duloxetine, and pregabalin has three concurrent medications — each with a different mechanism — all treating one condition. This three-drug pattern documents disease severity that a single medication prescription cannot convey, and the MERIT report explains the clinical rationale for each drug.

Defense Challenges and Responses

"Fibromyalgia Is Subjective and Not Verifiable"

The ACR 2010/2011 diagnostic criteria are standardized and widely accepted. Tonmya's FDA approval required demonstration of efficacy in randomized controlled trials — the gold standard of medical evidence. The FDA does not approve drugs for non-existent conditions.

"The Fibromyalgia Is Not Related to the Accident"

The pharmacy record shows when fibromyalgia-specific treatment began. If Tonmya was first prescribed 3-6 months after the accident with no prior fibromyalgia treatment history, the temporal relationship supports post-traumatic causation. The medical literature (Buskila et al.) establishes that fibromyalgia can develop after physical trauma.

"Standard Cyclobenzaprine Would Work"

Standard oral cyclobenzaprine is a short-term muscle relaxant — not a fibromyalgia treatment. Tonmya's sublingual formulation, low dose, and bedtime administration provide different pharmacokinetics optimized for sleep architecture and central pain modulation. The FDA approved Tonmya for fibromyalgia, not standard cyclobenzaprine.

"The Treatment Duration Is Excessive"

Fibromyalgia is a chronic condition. The ACR, the National Fibromyalgia Association, and the treating provider all recognize that ongoing pharmacological management is necessary. The pharmacy record documenting continuous treatment is evidence of chronic disease, not excessive prescribing.

Practical Steps for Attorneys

1. Identify post-traumatic fibromyalgia early — if your client develops widespread pain, fatigue, and sleep disturbance after an accident, discuss fibromyalgia screening with the treating provider
2. Ask about Tonmya — if the client is diagnosed with fibromyalgia, Tonmya's specificity strengthens the documentation
3. Refer for pharmacy lien coverage — LienScripts covers Tonmya and all fibromyalgia medications on lien with zero upfront cost
4. Document the pre-/post-accident timeline — the pharmacy record showing no fibromyalgia medications before the accident and Tonmya after establishes temporal causation

Frequently Asked Questions

For lien-based coverage of Tonmya and all fibromyalgia medications, LienScripts provides pharmacy services for personal injury patients with no upfront cost.

Related Resources

• 2026 FDA Drug Approvals Relevant to PI
• Case Study: Post-Traumatic Fibromyalgia
• Central Sensitization Medication: Attorney Guide
• Duloxetine for Chronic Pain After an Accident
• Pregabalin for Nerve Damage After a Car Accident